Ultromics, a U.K.-based healthcare technology company focused on cardiovascular imaging, has raised a total of $33 million Series B funding.
The new funds are expected to help Ultromics get its EchoGo Core and EchoGo Pro platforms in the hands of more healthcare providers and researchers. Both platforms were designed to diagnose conditions such as coronary artery disease, heart failure and amyloidosis through the use of AI-powered echocardiograms.
Multiple organizations in the United States, including Mayo Clinic and the Oregon Health and Science University, are already using and validating these solutions.
“Echocardiograms uploaded to the cloud and analyzed by AI are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy,” Ross Upton, PhD, CEO and co-founder of Ultromics, said in a statement.
The funding found was led by the Blue Venture Fund, a collaboration between dozens of Blue Cross Blue Shield companies and Sandbox. Optum Ventures, GV and Oxford Sciences Innovation all also participated.
“Cardiovascular disease is the leading cause of morbidity and mortality in the United States, and Ultromics offers groundbreaking AI solutions for more accurate diagnosis,” Emir Sandhu, MD, managing director at the Blue Venture Fund, said in the same statement. “We are excited to partner with Dr. Ross Upton and the Ultromics’ team as they promote improved patient outcomes.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.